Activation of Both MAP Kinase and Phosphatidylinositide 3-kinase by Ras is Required for Hepatocyte Growth Factor/scatter Factor-induced Adherens Junction Disassembly
Overview
Molecular Biology
Authors
Affiliations
Hepatocyte growth factor/scatter factor (HGF/SF) stimulates the motility of epithelial cells, initially inducing centrifugal spreading of colonies followed by disruption of cell-cell junctions and subsequent cell scattering. In Madin-Darby canine kidney cells, HGF/SF-induced motility involves actin reorganization mediated by Ras, but whether Ras and downstream signals regulate the breakdown of intercellular adhesions has not been established. Both HGF/SF and V12Ras induced the loss of the adherens junction proteins E-cadherin and beta-catenin from intercellular junctions during cell spreading, and the HGF/SF response was blocked by dominant-negative N17Ras. Desmosomes and tight junctions were regulated separately from adherens junctions, because they were not disrupted by V12Ras. MAP kinase, phosphatidylinositide 3-kinase (PI 3-kinase), and Rac were required downstream of Ras, because loss of adherens junctions was blocked by the inhibitors PD098059 and LY294002 or by dominant-inhibitory mutants of MAP kinase kinase 1 or Rac1. All of these inhibitors also prevented HGF/SF-induced cell scattering. Interestingly, activated Raf or the activated p110alpha subunit of PI 3-kinase alone did not induce disruption of adherens junctions. These results indicate that activation of both MAP kinase and PI 3-kinase by Ras is required for adherens junction disassembly and that this is essential for the motile response to HGF/SF.
MET Activation in Lung Cancer and Response to Targeted Therapies.
Okun S, Lu D, Sew K, Subramaniam A, Lockwood W Cancers (Basel). 2025; 17(2).
PMID: 39858062 PMC: 11764361. DOI: 10.3390/cancers17020281.
Hervieu A, Heuss S, Zhang C, Barrow-McGee R, Joffre C, Menard L Sci Signal. 2020; 13(637).
PMID: 32576681 PMC: 7329383. DOI: 10.1126/scisignal.aba8627.
Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G J Exp Clin Cancer Res. 2019; 38(1):494.
PMID: 31842953 PMC: 6916056. DOI: 10.1186/s13046-019-1494-3.
Park K, Geleta B, Leck L, Paluncic J, Chiang S, Jansson P J Biol Chem. 2019; 295(2):481-503.
PMID: 31744884 PMC: 6956523. DOI: 10.1074/jbc.RA119.011341.
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.
Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L Cancers (Basel). 2019; 11(10).
PMID: 31652660 PMC: 6827047. DOI: 10.3390/cancers11101618.